Procainamide: How It Works for Cardiac Arrhythmias

Procainamide is one of the oldest antiarrhythmic drugs still in clinical use, first introduced in the 1950s as a treatment for dangerous heart rhythm disturbances. It belongs to the Class IA category of antiarrhythmic agents, meaning it works primarily by blocking sodium channels in heart cells while also prolonging the electrical recovery period of cardiac tissue. Despite newer alternatives, procainamide retains a unique clinical niche, particularly for certain emergency arrhythmias and as a diagnostic tool for an inherited heart condition called Brugada syndrome.

How Procainamide Works on the Heart

Every heartbeat depends on a precise sequence of electrical signals moving through cardiac muscle. Sodium channels in heart cells open rapidly to initiate each beat, and the speed at which they open determines how fast the electrical impulse travels through the heart. Procainamide blocks these sodium channels, slowing the initial electrical impulse and making it harder for abnormal, rapid rhythms to sustain themselves. Research in animal models has confirmed that procainamide slows the upstroke of the cardiac action potential in a rate-dependent fashion, meaning the drug has a stronger blocking effect during fast heart rates than during normal ones.¹ This is a useful property: the drug hits hardest exactly when the heart is beating too fast.

What sets procainamide apart from some other sodium channel blockers is that it also lengthens the action potential duration, effectively extending the period during which heart cells are electrically “recharging” and cannot fire again. Studies comparing several antiarrhythmic agents have shown that while a drug like lidocaine mainly blocks sodium channels, and agents like N-acetylprocainamide primarily extend repolarization, procainamide exerts both effects.² This dual action gives it a broad reach against different types of arrhythmias but also accounts for some of its side effects, as we will see.

When Procainamide Is Used

Procainamide’s most prominent modern role is in the emergency treatment of stable ventricular tachycardia, a fast heart rhythm originating in the lower chambers of the heart. The American Heart Association gives procainamide a Class IIa recommendation for this situation, a stronger endorsement than the IIb given to both amiodarone and sotalol.³ In practice, many emergency departments still reach for amiodarone first simply because of habit and familiarity, but the evidence actually favors procainamide.

A randomized trial known as PROCAMIO directly compared intravenous procainamide to intravenous amiodarone for patients presenting with stable wide-complex tachycardia. About 9% of procainamide patients experienced a major cardiac adverse event, compared with roughly 41% of amiodarone patients. Procainamide also terminated the tachycardia within 40 minutes in about two-thirds of cases, versus just over a third with amiodarone.⁴ These results are striking, though the trial was relatively small, so the findings carry the caveat that larger confirmatory studies would strengthen the case.

Wolff-Parkinson-White Syndrome

Procainamide also has an established role in Wolff-Parkinson-White (WPW) syndrome, a condition where an extra electrical pathway between the upper and lower chambers of the heart can trigger dangerously fast rhythms, especially during atrial fibrillation. In WPW patients experiencing atrial fibrillation, the abnormal pathway can conduct impulses to the ventricles at extremely high rates, and certain drugs that slow the normal pathway without affecting the accessory one can actually make things worse. Procainamide slows conduction through the accessory pathway, buying time and reducing the ventricular rate. Studies have shown it significantly prolongs the shortest interval between pre-excited beats, a key marker of how much danger the accessory pathway poses.⁵ Propafenone, another antiarrhythmic, has a somewhat larger effect on this interval, but procainamide remains widely recommended because of its extensive track record in this setting.⁶

The NAPA Metabolite and Why It Matters

Once procainamide enters the body, the liver converts a portion of it into N-acetylprocainamide, commonly abbreviated NAPA. NAPA is not just an inactive waste product; it is pharmacologically active and has its own distinct effects on the heart. The conventional teaching has long been that NAPA acts as a “pure” Class III agent, meaning it extends the repolarization period of heart cells without blocking sodium channels the way procainamide does.⁷ Lab work in isolated cardiac tissue supports this at typical concentrations: procainamide both slows the upstroke and lengthens the action potential, while NAPA lengthens the action potential without changing the upstroke velocity.⁸

However, more recent research in guinea pig heart tissue has complicated this neat picture. When tested across a broader range of concentrations, NAPA did affect sodium channels at lower concentrations than expected, behaving more like a Class IA agent than a pure Class III one.⁹ The practical takeaway is that NAPA’s behavior may depend on the species studied and the drug concentration. For clinicians, the important thing is that NAPA accumulates when kidney function is impaired, and because it prolongs repolarization, high NAPA levels can independently cause dangerous heart rhythm problems. Monitoring combined procainamide and NAPA levels is standard practice during prolonged therapy.

Drug-Induced Lupus

The most notorious long-term side effect of procainamide is drug-induced lupus erythematosus, an autoimmune reaction that can produce joint pain, fever, skin rashes, and inflammation of the lining around the heart or lungs. Most patients on prolonged procainamide therapy develop antinuclear antibodies in their blood, but only about 15 to 20 percent go on to develop actual lupus-like symptoms.¹⁰ The mere presence of antinuclear antibodies, without symptoms, is not a reason to stop the drug.

Researchers have identified a specific antibody pattern that distinguishes people with symptomatic drug-induced lupus from those who just have positive blood tests. Patients with actual lupus symptoms almost always have elevated IgG antibodies directed against a histone complex called H2A-H2B, a marker that is both sensitive and specific for procainamide-induced lupus.¹¹ Antihistone antibodies more broadly are found in over 90% of patients with confirmed drug-induced lupus from procainamide.¹² These antibodies decline after the drug is stopped, and symptoms typically resolve over weeks to months.

Acetylator Status and Risk

People differ genetically in how fast their liver acetylates procainamide into NAPA. “Slow acetylators” convert the drug more slowly, leaving higher circulating levels of the parent compound. A landmark study found that slow acetylators developed antinuclear antibodies about two and a half times faster than rapid acetylators, with 50% of slow acetylators testing positive by about three months of therapy versus over seven months for rapid acetylators. Among patients who went on to develop full lupus symptoms, slow acetylators reached that point in roughly 12 months on average, while rapid acetylators took about four years.¹³

That said, the relationship between acetylator status and clinical lupus risk is not perfectly settled. A smaller study that used plasma-level monitoring to guide dosing found that both slow and rapid acetylators developed the lupus-like syndrome at similar rates (about 30% within a year), suggesting that when you adjust for actual drug exposure, the genetic difference may matter less than originally thought.¹⁴ In everyday practice, acetylator phenotype is not routinely tested before starting procainamide, but the risk of drug-induced lupus is a major reason prolonged oral procainamide therapy has fallen out of favor.

Other Cardiovascular Side Effects

Beyond lupus, procainamide carries several acute cardiovascular risks. Intravenous administration commonly causes a drop in blood pressure. A human study showed that a loading infusion lowered mean arterial pressure by about 7 mmHg, lowered central venous pressure, and reduced forearm vascular resistance, all pointing to significant vasodilation. The study also demonstrated that procainamide suppressed sympathetic nerve activity, meaning the usual reflex that would raise heart rate and constrict blood vessels in response to falling pressure was itself dampened by the drug.¹⁵ This is why IV procainamide is given slowly, typically over 20 to 50 minutes, with continuous blood pressure monitoring.

Because procainamide and its metabolite NAPA both prolong repolarization, the drug can cause QT prolongation and, in susceptible individuals, a dangerous polymorphic ventricular tachycardia called torsade de pointes. Procainamide, along with quinidine and disopyramide, is considered strongly associated with torsade de pointes among the Class I antiarrhythmics.¹⁶ The risk increases with higher drug and NAPA levels, electrolyte abnormalities (especially low potassium or magnesium), and underlying heart disease.

Drug Interactions

Because procainamide and NAPA are cleared substantially through the kidneys via tubular secretion, any drug that competes for the same transport system can raise circulating levels. One well-documented interaction involves trimethoprim, an antibiotic commonly prescribed for urinary tract infections (often combined with sulfamethoxazole as co-trimoxazole). In a controlled study, trimethoprim reduced the kidney’s clearance of procainamide by about 45% and that of NAPA by about 26%. This translated into a roughly 39% increase in procainamide exposure and a 27% increase in NAPA exposure.¹⁷ If you are on procainamide and prescribed an antibiotic containing trimethoprim, your doctor should consider monitoring drug levels or choosing a different antibiotic.

Other drugs known to interact include cimetidine (an older heartburn medication that also inhibits renal tubular secretion), amiodarone (which can raise procainamide levels when the two are used together), and certain other antiarrhythmics. The general principle is that any drug that impairs kidney function or competes for renal tubular transport can push procainamide and NAPA levels into the toxic range.

Dose Adjustments in Kidney Disease

Since both procainamide and NAPA depend heavily on kidney excretion, impaired kidney function dramatically alters the drug’s behavior. NAPA accumulation is particularly worrisome because the metabolite has a longer half-life than the parent drug and, as noted earlier, extends repolarization. Pharmacokinetic modeling in a patient receiving continuous renal replacement therapy suggested that roughly a 50% reduction in the regular maintenance dose was needed to keep concentrations within the therapeutic range.¹⁸ In any patient with reduced kidney function, combined procainamide and NAPA plasma levels should be monitored carefully, because toxicity can creep up even when the procainamide level alone looks safe.

Treating Procainamide Toxicity

Overdose or excessive accumulation of procainamide can produce widened QRS complexes on the ECG, dangerous drops in blood pressure, and potentially fatal arrhythmias. The primary treatment for serious cardiovascular toxicity from procainamide and related sodium channel blockers is intravenous sodium bicarbonate. The sodium load helps overcome the drug’s blockade of sodium channels, narrowing the QRS complex and improving conduction, while the alkalinization of the blood shifts the drug off its binding sites.¹⁹ ²⁰ Supportive measures include IV fluids for low blood pressure, correction of electrolytes, and temporary pacing if the heart rate drops dangerously. Hemodialysis can help remove both procainamide and NAPA from the blood, given their renal excretion pathway.

Unmasking Brugada Syndrome

Beyond treating arrhythmias, procainamide serves an important diagnostic purpose. Brugada syndrome is a genetic condition that predisposes people to sudden cardiac death from ventricular fibrillation, but its signature ECG pattern is often intermittent or hidden at rest. Infusing a sodium channel blocker like procainamide can provoke the telltale “type 1 Brugada pattern” on the ECG in people who carry the condition but whose resting tracings look normal or ambiguous. In a registry of cardiac arrest survivors with preserved heart function, procainamide infusion unmasked a type 1 Brugada pattern in 12 of 174 patients tested, including 5 whose baseline ECGs were completely normal.²¹

The test can also be applied to relatives of patients with known Brugada syndrome or survivors of unexplained sudden cardiac arrest. In one study of sudden unexplained death syndrome survivors and their families, procainamide infusion revealed the Brugada sign in 70% of survivors and about 15% of relatives using standard ECG leads. When higher intercostal space leads were added, the detection rate climbed to 90% of survivors and nearly 48% of relatives.²² Ajmaline, another sodium channel blocker, is more commonly used for this purpose in Europe, but procainamide remains the go-to provocative agent in many North American centers where ajmaline is not readily available.

Procainamide in Veterinary Medicine

Procainamide is not only a human drug. Veterinarians use it to manage certain arrhythmias in dogs, particularly ventricular tachycardia and premature ventricular complexes. One interesting difference from human medicine is that dogs appear to need substantially higher blood levels for the drug to work. In a study of dogs with digitalis-induced arrhythmias, all six animals converted to a normal heart rhythm, but the average effective plasma concentration was about 34 micrograms per milliliter, with a range up to nearly 49 micrograms per milliliter.²³ In human patients, therapeutic plasma concentrations are generally cited in the range of 4 to 12 micrograms per milliliter. This species difference is a reminder that drug doses and targets cannot be simply extrapolated across animals. Veterinary doses of procainamide are calculated specifically for dogs based on body weight, and the drug is given cautiously because hypotension and gastrointestinal side effects are common in canine patients as well.